{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:59Z","timestamp":1792269539391,"version":"4.4.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The introduction of innovative oncological therapies, such as immune checkpoint inhibitors (ICIs) and multikinase inhibitors (TKIs), has improved the prognosis of many malignancies but has introduced complex neuropsychiatric adverse events. This case report describes the management of a complex psycho-organic syndrome occurring in a patient treated with the combination of pembrolizumab and lenvatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 69-year-old woman, with a history of anxious-depressive disorder and recurrent endometrial carcinoma, was admitted for the onset of a sub-confusional state, severe psychomotor retardation, akathisia, and tremors. These symptoms appeared in temporal relationship with the initiation of combined pembrolizumab-lenvatinib therapy. Diagnostic investigations (CT, MRI, FDG-PET, and CSF analysis) excluded brain metastases or primary neuroinflammatory processes, revealing diffuse cortical hypometabolism consistent with metabolic-iatrogenic encephalopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management<\/jats:title>\n                    <jats:p>The therapeutic strategy involved a multidisciplinary approach based on the precautionary suspension of oncological drugs and a structured pharmacological washout. Flumazenil was administered with diagnostic-therapeutic success to correct GABAergic redundancy, and pramipexole was introduced to treat extrapyramidal manifestations and akathisia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights how overlapping immunological, vascular, and neuropharmacological effects can generate reversible encephalopathic patterns in complex oncological patients. Symptom resolution through psychopharmacological modulation and suspension of targeted treatment alone underscores the critical importance of active neuropsychiatric surveillance and close interdisciplinary collaboration between oncologists and psychopharmacologists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1904104","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:15Z","timestamp":1788948735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Neuropsychiatric and cognitive phenomena in a highly complex patient affected by psychiatric and oncological diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Anna","family":"Borghesani","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Bolzano Hospital","place":["Bolzano, Italy"]},{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiuscia","family":"Trottner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Bolzano Hospital","place":["Bolzano, Italy"]},{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian Max","family":"Wedmann","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Bolzano Hospital","place":["Bolzano, Italy"]},{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Bertoldi","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]},{"name":"Psychological Service, Bolzano Hospital","place":["Bolzano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tondulli","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]},{"name":"Department of Oncology, Bolzano Hospital","place":["Bolzano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Farsad","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]},{"name":"Department of Nuclear Medicine, Bolzano Hospital","place":["Bolzano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Spimpolo","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]},{"name":"Department of Nuclear Medicine, Bolzano Hospital","place":["Bolzano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Boschello","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Bolzano Hospital","place":["Bolzano, Italy"]},{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Bolzano Hospital","place":["Bolzano, Italy"]},{"name":"University Hospital of Psychiatry, Psychotherapy and Psychosomatics, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40520-021-01943-7","article-title":"The Montreal Cognitive Assessment (MoCA): updated norms and psychometric insights into adaptive testing from healthy individuals in Northern Italy","volume":"34","author":"Aiello","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"Journal of the American Geriatrics Society"},{"key":"B3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10072-018-3673-y","article-title":"Regression-based normative data and equivalent scores for Trail Making Test (TMT): an updated Italian normative study","volume":"40","author":"Siciliano","year":"2019","journal-title":"Neurological Sciences"},{"key":"B4","first-page":"111","article-title":"Una versione abbreviata del test di Stroop: dati normativi nella popolazione italiana","volume":"12","author":"Caffarra","year":"2002","journal-title":"Nuova Rivista di Neurologia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12883-022-02987-6","article-title":"A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study","volume":"22","author":"Hirano","year":"2022","journal-title":"BMC Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3892\/mco.2018.1777","article-title":"Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report","volume":"10","author":"Niki","year":"2019","journal-title":"Molecular and Clinical Oncology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2169\/internalmedicine.3782-19","article-title":"Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus","volume":"59","author":"Jono","year":"2020","journal-title":"Internal Medicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"109091","DOI":"10.1016\/j.clineuro.2025.109091","article-title":"Immune checkpoint inhibitor-induced encephalitis mimicking Wernicke encephalopathy \u2014 A case report","volume":"257","author":"Tan","year":"2025","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"B9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/medicina60050728","article-title":"Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission","volume":"60","author":"Civardi","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1605","DOI":"10.1002\/cnr2.1605","article-title":"Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer \u2014 A case report","volume":"5","author":"Mahajan","year":"2022","journal-title":"Cancer Reports (Hoboken)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/brainsci13010033","article-title":"Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma","volume":"13","author":"Tseng","year":"2022","journal-title":"Brain Sciences"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1209933","article-title":"Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Frontiers in Pharmacology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1904104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:17Z","timestamp":1788948737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1904104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":12,"alternative-id":["10.3389\/fpsyt.2026.1904104"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1904104","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1904104"}}